Rallybio Q3 net loss narrows to $11.5M; RLYB212 Phase 2 to screen in Q4

Rallybio Corp

2024-Q3 EPS reported -$1.08 revenue$598,000

Net loss $11.5M ($0.26/share) vs $18.4M ($0.45) in Q3 2023; revenue $0.3M from J&J collaboration.
Cash $75.1M as of Sep 30, 2024 provides runway into mid-2026; R&D expenses down 38% to $8.2M.
RLYB212 Phase 2 CTA approved by EMA and MHRA; screening for pregnant women at FNAIT risk to start Q4 2024.
RLYB116 manufacturing improvements completed; biomarker data suggests potential in PNH and APS beyond myasthenia gravis.
ENPP1 inhibitor candidate nomination with Exscientia on track for Dec 2024; preclinical data showed PPi reduction and improved bone mineralization.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.